The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to deliver a significant substantial decrease in body mass and enhance metabolic health, p